Cargando…

Network Analysis of a Membrane-Enriched Brain Proteome across Stages of Alzheimer’s Disease

Previous systems-based proteomic approaches have characterized alterations in protein co-expression networks of unfractionated asymptomatic (AsymAD) and symptomatic Alzheimer’s disease (AD) brains. However, it remains unclear how sample fractionation and sub-proteomic analysis influences the organiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Higginbotham, Lenora, Dammer, Eric B., Duong, Duc M., Modeste, Erica, Montine, Thomas J., Lah, James J., Levey, Allan I., Seyfried, Nicholas T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789842/ https://www.ncbi.nlm.nih.gov/pubmed/31461916 http://dx.doi.org/10.3390/proteomes7030030

Ejemplares similares

Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome
por: Dammer, Eric B., et al.
Publicado: (2022)

Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease
por: Donovan, Laura E, et al.
Publicado: (2013)

Correction to: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer’s disease
por: Donovan, Laura E., et al.
Publicado: (2021)

Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease
por: Modeste, Erica S., et al.
Publicado: (2023)

Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease
por: Higginbotham, Lenora, et al.
Publicado: (2020)

Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease
por: Dai, Jingting, et al.
Publicado: (2018)

Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s Disease
por: Ping, Lingyan, et al.
Publicado: (2018)

Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer’s Disease
por: Watson, Caroline M., et al.
Publicado: (2023)

A proteomic network approach across the ALS‐FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain
por: Umoh, Mfon E, et al.
Publicado: (2017)

Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease
por: Johnson, Erik C. B., et al.
Publicado: (2018)

Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer’s disease
por: Ping, Lingyan, et al.
Publicado: (2020)

Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau
por: Rayaprolu, Sruti, et al.
Publicado: (2020)

Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer’s disease-related proteins
por: Rangaraju, Srikant, et al.
Publicado: (2018)

Identification of Conserved Proteomic Networks in Neurodegenerative Dementia
por: Swarup, Vivek, et al.
Publicado: (2020)

Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease
por: Zhou, Maotian, et al.
Publicado: (2020)

Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease
por: Rangaraju, Srikant, et al.
Publicado: (2018)

Targeted Quantification of Detergent-Insoluble RNA-Binding Proteins in Human Brain Reveals Stage and Disease Specific Co-aggregation in Alzheimer’s Disease
por: Guo, Qi, et al.
Publicado: (2021)

U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer’s disease due to autosomal dominant genetic mutations and trisomy 21
por: Hales, Chadwick M, et al.
Publicado: (2014)

Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease
por: Rayaprolu, Sruti, et al.
Publicado: (2020)

Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain
por: Wingo, Aliza P., et al.
Publicado: (2020)

Differential Phagocytic Properties of CD45(low) Microglia and CD45(high) Brain Mononuclear Phagocytes—Activation and Age-Related Effects
por: Rangaraju, Srikant, et al.
Publicado: (2018)

Proteomics of protein post-translational modifications implicated in neurodegeneration
por: Ren, Ru-Jing, et al.
Publicado: (2014)

Proteomic Analysis of Hippocampal Dentate Granule Cells in Frontotemporal Lobar Degeneration: Application of Laser Capture Technology
por: Gozal, Yair M., et al.
Publicado: (2011)

Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis
por: Wingo, Aliza P., et al.
Publicado: (2021)

Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations
por: Huang, Meixiang, et al.
Publicado: (2020)

Machine Learning Selection of Most Predictive Brain Proteins Suggests Role of Sugar Metabolism in Alzheimer’s Disease
por: Tandon, Raghav, et al.
Publicado: (2023)

Coaggregation of RNA-Binding Proteins in a Model of TDP-43 Proteinopathy with Selective RGG Motif Methylation and a Role for RRM1 Ubiquitination
por: Dammer, Eric B., et al.
Publicado: (2012)

Genetic background influences the 5XFAD Alzheimer’s disease mouse model brain proteome
por: Hurst, Cheyenne D., et al.
Publicado: (2023)

Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age
por: Wingo, Aliza P., et al.
Publicado: (2019)

Proteomic Network Analysis of Alzheimer’s Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE ε4 Genotype and Atomoxetine Treatment
por: Dammer, Eric B., et al.
Publicado: (2023)

TBK1 interacts with tau and enhances neurodegeneration in tauopathy
por: Abreha, Measho H., et al.
Publicado: (2021)

Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer’s Disease
por: Hurst, Cheyenne, et al.
Publicado: (2023)

Genetic background influences the 5XFAD Alzheimer's disease mouse model brain proteome
por: Hurst, Cheyenne D., et al.
Publicado: (2023)

Integration of plasma and CSF metabolomics with CSF proteomic reveals novel associations between lipid mediators and central nervous system vascular and energy metabolism
por: Borkowski, Kamil, et al.
Publicado: (2023)

A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation
por: Rangaraju, Srikant, et al.
Publicado: (2017)

Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease
por: Borkowski, Kamil, et al.
Publicado: (2021)

Quantitative proteomic analysis of the lysine acetylome reveals diverse SIRT2 substrates
por: Zhang, Hui, et al.
Publicado: (2022)

The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease
por: Wang, Minghui, et al.
Publicado: (2018)

CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease
por: Hu, William T., et al.
Publicado: (2016)

Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level
por: Johnson, Erik C. B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3vn07off26ud9sjvuugdoopb4q